Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 10/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14670098 | 0.95 | PLA2G7 (0.47) | PLA2G7GPR84HTR2CP2RX3GRM5 | |
| SCHEMBL14656392 | 0.90 | PLA2G7 (0.44) | PLA2G7GPR84 | |
| SCHEMBL14656130 | 0.89 | PLA2G7 (0.49) | PLA2G7GPR84GRM5 | |
| SCHEMBL14656164 | 0.88 | PLA2G7 (0.51) | PLA2G7GPR84GRM5 | |
| SCHEMBL14656120 | 0.86 | PLA2G7 (0.52) | PLA2G7 | |
| SCHEMBL14663585 | 0.86 | PLA2G7 (0.51) | PLA2G7GPR84HTR2CP2RX3GRM5 | |
| SCHEMBL14656263 | 0.86 | PLA2G7 (0.52) | PLA2G7GPR84 | |
| SCHEMBL14663519 | 0.85 | PLA2G7 (0.51) | PLA2G7GPR84GRM5 | |
| SCHEMBL14656274 | 0.85 | GPR84 (0.49) | GPR84GRM5CYP11B1CYP11B2 | |
| SCHEMBL15813992 | 0.85 | PLA2G7 (0.47) | PLA2G7GPR84HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2736908-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | Glaxo Group Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | PLA2G7 1/4885GPR84 911/4885HTR2C 3165/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | PLA2G7 2/4885GPR84 847/4885HTR2C 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.